Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues an exclusive podcast interview with David Schrader, Chief Operating Officer at Scythian Biosciences Corp. (TSXV: SCYB).

Scythian Biosciences Corp. seeks to develop the first accepted drug regimen for concussion and traumatic brain injury with their cannabinoid-based combination drug therapy.

"There is no currently accepted drug regimen for the treatment of traumatic brain injury and concussion," said Scythian's Chief Operating Officer, David Schrader.

Schrader explained that after sustaining an injury to the head, further damage is often caused by the body's natural responses.

"Aside from the initial impact, there's a couple of processes that happen in the brain that cause continuing brain injury even after the initial injury occurs," he said. "The process of inflammation, and the body's own immune response, which releases things such as cytokines, which are different chemicals in the immune process and they trigger other immune processes."

Schrader said that the company's research had led them to the use of cannabinoids.